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With the evolution of the treatment of malignant neoplasms, the survival rates of patients undergoing chemo- or radiotherapy
are increasing. The continuous development of techniques of assisted human reproduction has led to important strategies in an
attempt to maintainreproductive function in patients subjected to treatment of neoplasticdiseases,amongthem cryopreservation
of embryos, gametes, and ovarian cortical tissue. The freezing of ovarian tissue is currently being proposed with the primary
purpose of preserving ovarian function in these patients. Currently, the major challenge of groups working with preservation
of fertility is the use of cryopreserved ovarian tissue after disease remission. The main alternatives presented today are the
implantationofhetero- ororthotopictissueandisolationofimmaturefolliclesfromovariantissuefollowedby in vitro maturation
and assisted reproduction procedures.
1.Introduction
Invasive cancer is diagnosed in more than 600,000 persons
peryearintheUnitedStates,with269,800ofaﬀectedpatients
being women, 8% of whom are younger than 40 years [1].
With the use of modern protocols for the treatment of
cancer, 80%ofthepatientswill survive. Ithasbeenestimated
that, over the next few years, one in each 250 young adult
womenwillbeasurvivorofchildhoodcancer,withsomeside
eﬀects[2, 3]. One ofthe main problems, especially for young
patients, is that therapy destroys a signiﬁcant proportion of
the follicular population, a fact that may result in permanent
infertility [3–5].
Although treatment and survival are the main focus of
both health professionals and cancer patients, it is important
to consider the quality of life of the latter after treatment,
including the possibility to have children [6].
The cytotoxic action of ionizing radiation and chem-
otherapeutic agents frequently leads to the occurrence of
premature ovarian failure (POF), with serious long-term
consequences such as reduction of bone mass leading to
osteoporosis, to an increased incidence of cardiovascular
diseases, and to the premature onset ofclimacteric and infer-
tility symptoms [7]. The temporary or permanent absence
of the endocrine and reproductive ovarian functions mainly
depends on the age of the patient at the time of gonadotoxic
treatment and on the doses administered. The risk of in-
fertility varies according to treatment and to the type of
chemotherapy based on alkylating agents and platinum,
which have a greater potential to damage the reproductive
system [6, 8, 9]. Several types of cancer treatment can cause
infertility in patients looking for a cure. Some chemotherapy
protocols can cause POF or acute ovarian insuﬃciency
during or soon after cancer treatment.
The occurrence of POF is observed in 69% of patients
aged up to 29 years and in 96% of patients aged 30 years
or older after chemotherapy for the treatment of Hodgkin’s
disease [7].Forwomensubmittedtoradiotherapywith doses
higherthan300cGy,theincidenceofPOFcanbehigherthan
60%, with the exposure to 4Gy ofpelvic irradiation being le-
thal for the oocytes, and the exposure to 5 to 10.5Gy leading
to ovarian failure in 97% of patients. The combination of2 ISRN Obstetrics and Gynecology
chemotherapy and radiotherapy is particularly devastating.
However,studieson women who conceivedafterchemother-
apy did not detect a signiﬁcant increase in congenital mal-
formations or malignant neoplasias in the oﬀspring [5, 10–
12].
More and more patients are currently surviving can-
cer thanks to an early diagnosis and adequate treatment.
Although surviving adults tend to be more interested in the
preservation of fertility, it is important to remember that
other options should be made available to young cancer
patients. Health professionals should be prepared to discuss
fertility with their patients regardless of the age or marital
status ofthe latterat the time when therapy is started, so that
they may understand the possible consequences of cancer
treatment and the alternatives available for the preservation
of fertility [13].
Other groups of patients may be candidates for the pre-
servation of fertility, such as women with endometriosis and
patients treated with chemotherapeutic agents for nonma-
lignant diseases such as autoimmune and collagen-vascular
conditions. Persons with deﬁciencies in DNA repair are also
more susceptible to gonadotoxicity [13, 14]. Other cases
include the incompatibility between age of maternity and
career plans or simply women who have not yet found the
desired partner in order to start a family [15].
The continuous evolution of assisted human reproduc-
tion techniques has permitted several strategies to be consid-
ered for the maintenance of reproductive function in female
patients who complete treatment for neoplastic diseases,
such as hormone manipulation, ovary transposition, and
cryopreservation of embryos, gametes, and ovarian cortical
tissue.
2.CryoprotectorsandFreezing Methods
Cryopreservation consists of the preservation of biological
material at low temperatures, usually in liquid nitrogen at
−196◦C, or in the vapor phase of nitrogen at −150◦C. The
onlyphysicalstatesexisting belowapproximately −130◦Car e
the crystalline and the vitreous ones. In both states, viscosity
is quite high, diﬀusion is considered to be nonsigniﬁcant
(depending on storage time), the molecular kinetic energy is
very low, and metabolic reactions driven by thermal energy
occur very slowly or are completely paralyzed. Thus, at the
temperature of liquid nitrogen, viability during storage can
be extended over long periods of time, with maintenance
of the stability of genetic material. The ability of biological
material to survive the cryopreservation process depends on
its tolerance of cryoprotective agents, dehydration, cooling
and reheating [16].
Cryoprotective agents are substances that protect cells
against dehydration, cooling, and damage caused by extreme
temperature reduction. In general, these agents can act by
(1) penetrating the cells (intracellular cryoprotectors) and
replacing the water molecules of the cell, (2) reducing the
freezingpoint,(3)protectingthecellmembranes(extracellu-
lar cryoprotectors) by binding to the heads of the phospho-
lipid groups, (4) increasing the viscosity of the medium, or
(5)reducingtheelectrolyteconcentrationduringcryopreser-
vation, thus reducing the risk of osmotic damage. However,
the cryoprotective agents can be toxic and can also facilitate
the entry of toxic agents into the cells [17].
The use ofcryoprotectorsreducescell damage during tis-
sue preservation, although cryoprotectors are indispensable
for a successful process, cytotoxicity may occur in cases of
prolonged exposure to these agents, with a l5–90% loss of
primordialfolliclesoccurringaccordingtotheprotectorused
[18]. The cryoprotective agents may be alcohols, amines,
sugars, and proteins, and their eﬀectiveness depends on
some properties such as high solubility in water in order
to minimize the osmotic gradient and to reduce toxicity.
The most common cryoprotective solutions consist of the
following combinations: (a) dymethyl-sulfoxide and human
serum, (b) 1.5M ethylene glycol, 1.5M dymethyl-sulfoxide
and fetal calf serum, and (c) 1-2-propanediol, 0.1M sucrose,
and human serum albumin [19].
2.1. Slow Freezing. Slow freezing is characterized by cell or
tissue exposure to low concentrations of the cryoprotective
agentforaperiodoftimerangingfrom20to60min [20–23].
With this method, the material is cooled slowly at the rate
of 2◦C/min to −4t o−9◦C and is kept at this temperature
for a short period of time (10 to 15min) for thermal
stabilization and seeding, which prevents supercooling and
extreme cell dehydration. The sample then continues to be
cooled slowly at the rate of 0.3◦C/min. Once a suﬃcient cell
dehydrationisreached(−30to −80◦C),thematerialisstored
in liquid nitrogen (−196◦C). This technique has proved to
be eﬀectivefor the conservation ofovarian tissue [24, 25]. Its
use requires speciﬁc high-cost equipment but, on the other
hand, it requires lower cryoprotector concentrations, with
less toxicity to the cells.
2.2.Vitriﬁcation. Vitriﬁcationwasﬁrst conceivedbyLuyetin
1937 and almost 50 years later Rall and Fahy [26] described
vitriﬁcation as an alternative to the process of slow freezing.
In contrast to slow freezing, vitriﬁcation involves the expo-
sure of biological material to high concentrations of the
cryoprotective agent for a short period of time (25 seconds
to 5min) usually at room temperature, followed by ultra-
rapid cooling in liquid nitrogen, without the need to use
sophisticated and highly expensive equipment. According to
Stachecki and Cohen [27], vitriﬁcation involves two basic
aspects to be taken into consideration; the ﬁrst consists of
the fact that the high concentrations of cryoprotective agents
used for exposure increase the toxic eﬀects, and the second
is that, despite this eﬀect during the period of equilibrium,
vitriﬁcation, by involving very rapid freezing, increases the
survival rates. Vitriﬁcation has been successfully used for
ovarian tissue, with minimal changes in tissue morphology
[28, 29].
Althoughbothtechniquesare beingcontemplatedforthe
clinical application of embryo, gamete, and ovarian tissue
c r y o p r e s e r v a t i o n ,t h et e c h n i q u eo fc h o i c ef o rt h ep r o c e d u r e
variesaccordingtothetypeofmaterialtobeconserved,with-
out full consensus among authors.ISRN Obstetrics and Gynecology 3
3.ClinicalApplicationsofEmbryo,Gamete,and
OvarianTissue Cryopreservation
3.1. Embryo Cryopreservation. The only method established
thus far and routinely used at assisted reproduction clinics
is embryo cryopreservation. However, this option requires
ovarian stimulation,oocytecollection,and theuseofassisted
reproduction techniques that may take 2 to 5 weeks. Thus,
the delay of chemotherapy prior to embryo storage is not
feasible for some patients and may even lead to a worse
prognosis for some cancer types. Embryo freezing also does
not apply to patients without a steady partner with whom
they wish to produce oﬀs p r i n gi nt h ef u t u r e ,a si st h ec a s ef o r
adolescents. An alternative would be the use of semen from
a bank, although this option involves religious, moral, and
ethical questions [3, 8].
In addition, stimulation should not be performed in
women with hormone-dependent tumors such as breast
cancer although new stimulation protocols have arisen with
the use tamoxifen and of aromatase inhibitors (Letrozole),
showing encouraging results [30]. On this basis, embryo
freezing should be considered as the ﬁrst option for the
preservation of fertility in women with a steady partner who
are in a condition to be submitted to at least one in vitro
fertilization (IVF) cycle and is currently the only technique
oﬃcially recognized by the American Society of Clinical
Oncology for the preservation of fertility [31]. Although this
is the recommendation, it is important to emphasize that a
successful preservation of fertility is not guaranteed in view
of the limitation of the number of embryos that can be
obtained and frozen in a stimulation cycle.
It should be remembered that the rates of live births
after embryo freezing-thawing depend on patient age and
on the number and quality of cryopreserved embryos. Based
on these variables, the mean pregnancy rate after embryo
freezing-thawing is about 20 to 30% with the transfer of 2
to 3 embryos and the rate of live born babies per embryo
transfer cycle is 27.7%, as reported by the Center for Disease
Control and Prevention [32] (2006 data). Although oocytes
can be retrieved without ovarian stimulation (natural cycle),
the ﬁnal yield of embryo production in nonstimulated cycles
is extremely low [31] and therefore not recommended for
cancer patients [30].
Another point to be remembered concerns the ethical
implications of embryo freezing. Since cancer is a disease
with a potentially unfavorable outcome leading to patient
death, couples should be informed about the lack of ethical
or legal possibility of disposal of these embryos in case of
death of one spouse. Furthermore, even if oncologic treat-
ment is successful, embryo transfer to the uterus will occur
only after several years of disease remission and, regardless
of the situation of the relationship of a couple after these
years, the embryos exist and need a destination either to the
maternal uterus or to donation for research.
Some ethical questions should be raised regarding the
decision to be made by the couple: if the maternal partner
dies, what is the right of the male partner (father) to these
embryos? In this case, would it be possible to transfer these
embryos to a new female partner of this biological father?
How would the family of the deceased biological mother ﬁt
within thiscontext?TheBrazilian legislationhas norepliesto
these questions, and there is no law regarding thedestination
of frozen embryos. All current conducts are based on the
judgment of the team that assists the patient, on good
counseling of the couple, and on the recommendations of
the Federal Council of Medicine.
3.2. Cryopreservation of Mature Oocytes. Oocyte cryopreser-
vation obviates many of these ethical questions associated
with embryo cryopreservation. This technique has arisen as
an alternative for the preservation of fertility and has the
great advantage of being able to be used by women without a
deﬁned sex partner. However, a cycle of ovarian stimulation
is required before the beginning of chemotherapy. Although
the ﬁrst birth obtained from frozen oocytes was reported by
Chen in 1986, the results obtained at the time using IVF of
thawed oocytes were poor, with low rates of oocyte survival,
fertilization, and pregnancy [14]. However, starting in 2005,
with the use of oocyte vitriﬁcation techniques there was an
increase in the rate of survival of frozen-thawed oocytes and
also of pregnancy [33]. Kuwayama et al. [34] developed as
speciﬁc system for specimen storage and revolutionized the
results of oocyte freezing using the vitriﬁcation technique.
In 2005, the authors obtained a 91% rate of oocyte survival
after freezing-thawing, an 81% cleavage rate, a 50% rate of
blastocystformation,and a41%pregnancyrateafter embryo
transfer. Antinori et al. [35] obtained a 99.4% rate of oocyte
survival, with fecundation, pregnancy, and implantation
rates of 92.9, 32.5, and 13.2%, respectively, and Cobo et al.
[36] obtained a 96.6% rate of oocyte survival, with a 65%
pregnancy rate.These resultsaresimilar tothosereportedfor
fresh oocytes and indicate a revolution in the techniques of
gamete cryopreservation. Despite these results, the freezing
of mature oocytes is still considered to be experimental by
the American Society of Clinical Oncology [31].
3.3. Cryopreservation of Immature Oocytes. This method
emerged as an alternative to the freezing of mature oocytes
s i n c ei m m a t u r eo o c y t e sa r eb e l i e v e dt ob em o r er e s i s t a n t
to the freezing process by being more undiﬀerentiated,
by the absence of a spindle and by having chromosomes
protected by a nuclear membrane. Some authors propose
the puncture of still immature oocytes and the application
of in vitro maturation (IVM) techniques associated with the
cryopreservation of these gametes in order to minimize the
timeofinductionandreducethecostsandsideeﬀectsofcon-
trolled ovarian hyperstimulation [30, 37]. However, results
regarding oocyte survival and maturation up to metaphase
II do not seem to be very encouraging. This method will not
be valid until IVM of oocytes becomes a routine procedure
[38].
3.4. Cryopreservation of Cortical Ovarian Tissue. The cry-
opreservation of ovarian tissue is based on the principle
that inactive (primordial) follicles resist cytotoxicity better
than follicles in the process of maturation [39]s i n c et h e i r
metabolism is reduced, the zona pellucida is absent, and4 ISRN Obstetrics and Gynecology
the cryoprotectors can penetrate more easily due to the
smaller follicular size [40]. In addition, primordial follicles
have a greater potential for the repair of damage suﬀered by
the organelles and by other structures during the prolonged
freezing phase in cryopreservation.
The functional cell damage caused by cryopreservation,
however, can be irreversible if the temperature falls below
ideal levels. Very abrupt thermal variations may interfere
with water transport through the cell membrane and favor
the formation of ice crystals and salt deposits inside the cell
[41]. The diﬀerences in osmotic pressure between the intra-
and extracellular media may also lead to a change in oocyte
volume, with consequent damage to the plasma membrane
and to the organelles [42]. Another factor that may favor cell
damage is the presence of meiotic spindles in the follicular
cells. It has been demonstrated that small variations in
temperature can damage the microtubules that compose the
spindle, possibly leading to chromosome losses and aneu-
ploidies during the end of the ﬁrst meiotic division in the
subsequent maturation process. In addition, it has also been
demonstrated that freezing can damage the cytoskeleton of
the cell or the oocytes, with impaired transit of molecules
and organelles during the process of cell division. The phase
of tissue reexpansion (thawing) can also be deleterious if the
external medium is not adequate [43].
The freezing of ovarian tissues is being currently pro-
posed mainly in order to maintain preserved ovarian func-
tion in terms of both fertility and hormone production,
a goal that is not reached with the remaining methods.
In addition, this option currently emerges to serve speciﬁc
groups of patients for whom the remaining techniques are
not recommended, such as (1) prepubertal patients whose
gonads are not yet under the control of the hypothalamus-
pituitary axis, (2) women without a partner who do not
desire embryos obtained by fertilization with donor semen,
(3) patients with estrogen-dependent neoplasias such as
breast cancer, and (4) women with malignant neoplasias
which require an immediate approach, for whom a delayed
onset of treatment for the time needed to induce ovulation
may lead to changes in prognosis. Particularly regarding this
aspect,thecollectionofcorticalovariantissueforcryopreser-
vation has the advantage of being possible to perform at any
time during themenstrual cycleofthepatient and ofpermit-
ting the acquisition of hundreds of primordial follicles. The
disadvantages of the cryopreservation of cortical ovarian tis-
sue deserve some comment and consist of (1) submitting the
patient to surgical procedures for the collection of ovarian
tissue and (2) the possibility of reintroducing malignant cells
at the time of later tissue reimplantation [44, 45].
The procedures of cryopreservation should guarantee
follicular viability and tissue integrity in cell-to-cell contact.
Today, the slow cooling method is being essentially used in
clinical programs. Vitriﬁcation of the ovarian cortex, a sup-
plementary technique which is currently being developed,
has also elicited considerable interest [46].
In the ovaries of adult mammals, the follicles are present
in various stages of development. Primordial follicles can
be considered to the “storage form” of oocytes in the
ovary, representing a valuable source of oocytes that could
be used for fertility purposes [47, 48]. Although many
authors believe that freezing ovarian tissue is a promising
technique for the preservation of fertility, damage to the fol-
licularnucleusand DNAofsheep and humansafterfreezing-
thawing has been reported in studies using immuno-
histochemistry, ﬂuorescent in situ hybridization, and ﬁnal
labeling of the deoxynucleotidyl transferase terminal [12,
49].
The process of ovary freezing and thawing can cause tis-
sue damage, possibly dueto theformation ofintracellular ice
and to the toxicity of the cryopotectors [50]. Once the ovary
is cryopreserved, the major challenge of this technique as
a method for the preservation of fertility is the later use
of thawed tissue. Among the possibilities considered, there
is the reimplantation of tissue as a whole or as fragments
[51] or the isolation of immature follicles by a digestion
technique or by microdissection, followed by IVM of pri-
mordial and primary follicles [52]. It should be pointed out
that many researchers have invested in IVM of primordial
follicles.
Regarding reimplantation of thawed ovarian tissue, the
majorobstaclesinthewayofsuccessfulrestorationoffertility
with frozen-thawed ovarian cortex are adherences and mas-
sive ischemic damage to the follicles until the development
of neovascularization. Most of the follicles that survive
cryopreservation suﬀer ischemia during the time needed for
neorevascularization [12].
Cortical ovarian tissue can be collected by laparoscopy or
laparotomy by obtaining various biopsies, or by total or par-
tial uni-or bilateral oophorectomy followed by cryopreserva-
tion of the tissue [45]. The protocols most extensively used
tofreeze ovarian tissueinvolvetechniquesofslowprogressive
(ramp) freezing [24] and vitriﬁcation in liquid nitrogen
[34].
Eﬀorts are currently directed at the attempt to eluci-
date the potential of frozen-thawed ovarian tissue for the
maintenance of reproductive capacity using either in vitro
maturation of isolated oocytes or autotransplantation of
cryopreserved tissue [52].
3.4.1. Tissue Reimplantation after Freezing and Thawing.
Several studies were conducted in the ﬁfties regarding ovary
cryopreservation and transplantation. Gosden et al. [24]i n
1994 obtained successful restoration offertility in sheep after
autologous transplantation of frozen-thawed ovarian tissue
and showed new perspectives for the technique, especially
as a strategy to preserve ovarian function in women with
cancer.
Frozen-thawed ovarian tissue can be transplanted in two
ways: orthotopic transplant—the ovary or ovary fragment
is placed in the ovarian fossa close to the infundibulo
pelvic ligament, and heterothotopic transplant—the tissue is
implantedatany siteoutsideitsoriginallocus.Aspontaneous
pregnancy can be theoretically obtained in a patient with
pervious tubes. When the heterotopic transplant is used,
pregnancy will only be possible using assisted reproduction
procedures [53]. Considerable success has been achieved in
terms of restoration of hormonal cyclicity in patients and,
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as a result of transplanting frozen/thawed ovarian tissue
[52].
3.4.2. In Vitro Maturation (IVM). The current great chal-
lengeforgroupsworkingwithfertilitypreservationistheuti-
lization of cryopreserved ovarian tissue after disease remis-
sion. As mentioned earlier, there are two major alternatives:
reimplantation of hetero- or orthotopic tissue and isolation
of immature follicles from ovarian tissue followed by IVM
and assisted reproduction procedures. The ﬁrst option, in
addition to involving technical diﬃculties related to graft
ischemia, also involves the possibility of reimplantation of
tumor cells together with tissue. On this basis, IVM becomes
an option of high clinical relevance in which much research
has been invested.
The maturation ofmammalian oocytesis a complexpro-
cessinvolving the resumption and progression of the meiotic
cycle and the reprogramming of cytoplasmic events, pre-
requisites for monosperm fertilization and early embryo
development [52].
In vivo, the occurrence of oocyte maturation is charac-
terized by the high developmental potential of the cell after
fertilization. However, under experimental conditions (IVM
or superovulation techniques), the quality of the oocyte is
drastically reduced. This limiting step in the technology of
in vitro embryo production has led to the formulation of
diﬀerent IVM methods based on culture media with cells or
tissues added and/or supplemented with biological ﬂuids in
an attempt to mimic the events that occur in the follicular
microenvironment [54–61].
The current scientiﬁc production about IVM mainly
involves the maturation of immature oocytes already in the
process of development(germinal vesicle).However, follicles
isolated from ovarian tissue are still in a primordial and
primary stage. The literature about these follicles is quite
scarce, although several investigations have been conducted
in order to improve the rate of in vitro maturation of these
oocytes [62].
4.Final Considerations
Fertility preservation continues to advance with innovative
investigations carried out in order to obviate the damage
caused by oncologic treatment or even to help women who
opt for a late pregnancy. Each method has advantages and
limitations and all procedures involve social, ethical, and
legal considerations. The techniques available to women
who try to preserve fertility are embryo cryopreservation,
oocyte cryopreservation, and ovarian tissue cryopreserva-
tion.Today,embryocryopreservationistheoﬃcialsuccessful
method of fertility preservation although its use is limited
to women who have husbands or male partners or male
partners who are willing to use sperm cryopreservation.
The techniques of ovarian tissue or oocyte cryopreservation
are still considered to be experimental. These methods
will permit girls and young women to become parents
in the future even after exposure to chemotherapy or to
other agents that might cause infertility. The prevention of
reproductive failure would be an ideal approach and several
studies on this topic are currently underway.
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